Key Findings:  Resulting data revealed that treatment with Beta-Caryophyllene (BCP), CBD, and their combination was associated with a significant decrease in infarct size.
Type of Study:  Animal Study
Study Result:  Positive
Research Location(s):  United States
Year of Pub:  2021
Cannabinoids Studied:  Cannabidiol (CBD)
Phytocannabinoid Source:  Unspecified
Chemotype:  Chemotype III
Terpenes Studied:  ß-Caryophyllene
Receptors Studied:  CB2
Dosage: Beta-Caryophyllene (BCP) (3–30 mg/kg IP) and CBD (3–30 mg/kg IP), given alone or in combination (30:3, 30:10, and 30:30 BCP:CBD)
Route of Administration:  Injection
Citation:  Yokubaitis CG, et al. Effects of Cannabidiol and Beta-Caryophyllene Alone or in Combination in a Mouse Model of Permanent Ischemia. Int J Mol Sci. 2021; 22:(unknown pages). doi: 10.3390/ijms22062866
Authors:  Yokubaitis CG, Jessani HN, Li H, Amodea AK, Ward SJ